1106 Fin Apollomics
BioCentury & Getty Images

Finance

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

Ping An Capital leads series C round for cross-border cancer in-licensing play

Cross-border play Apollomics raises a series C led by Ping An Capital and backed by a broad syndicate of Asian investors to in-license and develop cancer therapeutics.

Nov 7, 2020 | 2:38 AM GMT

Apollomics

Read the full 684 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE